financetom
Business
financetom
/
Business
/
GE HealthCare's Q1 Earnings Miss Wall Street Projections, But It Sticks To Annual Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GE HealthCare's Q1 Earnings Miss Wall Street Projections, But It Sticks To Annual Guidance
Apr 30, 2024 9:00 AM

GE Healthcare Technologies Inc ( GEHC )  reported first-quarter sales of $4.6 billion, down 1% Y/Y, and were approximately flat on an Organic basis, with decreased volume partially offset by positive price, missing the consensus of $4.8 billion.

Net income attributable to GE HealthCare ( GEHC ) was $374 million versus $372 million for the prior year, and Adjusted EBIT was $681 million versus $664 million.

Total company book-to-bill was at 1.03 times, defined as Total orders divided by Total revenues. Total company orders increased by 1% organically year-over-year.

The company posted an adjusted EPS of $0.90, compared to $0.85 in the prior year, missing the consensus of $0.91.

Imaging segment revenues of $2.5 billion, down 1% Y/Y on the reported basis and flat organically.

Ultrasound segment revenues of $824 million declined by 4% on both reported an Organic basis.

Patient Care Solutions' Revenues of $747 million decreased by 4% on reported and organic basis. Pharmaceutical Diagnostics' revenues of $599 million increased by 7% reported and 8% on an Organic basis.

Citing BTIG analyst, Reuters noted that "many of GE HealthCare's ( GEHC ) suppliers were noting weakness in China last quarter, so it makes some sense that we would see that come through (to this quarter)."

Management struck an upbeat tone, "We delivered margin expansion while continuing to invest in innovation to solve the evolving needs of customers and patients," said CEO Peter Arduini in a news release. "This is reflected in our healthy backlog, orders growth, and positive book-to-bill…we expect to see business growth weighted toward the second half of 2024 consistent with our previous comments, and we remain on track to deliver our guidance for the year."

Guidance: GE Healthcare ( GEHC ) reaffirms its full-year 2024 guidance, with organic revenue growth of approximately 4% Y/Y and an adjusted EBIT margin of 15.6%-15.9%.

The company expects 2024 adjusted EPS of $4.20-$4.35 versus consensus of $4.30.

Price Action: GEHC shares are down 12.90% at $77.49 at the last check Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Saudi Aramco Signs 17 US MoUs, Agreements With US Companies
Saudi Aramco Signs 17 US MoUs, Agreements With US Companies
Nov 19, 2025
12:46 PM EST, 11/19/2025 (MT Newswires) -- Saudi Aramco said Wednesday it has signed 17 memoranda of understanding and agreements worth potentially about $30 billion with US companies via its Aramco Group Companies. The latest announcement expands on earlier commitments in May worth about $90 billion, the company said. Aramco said the new investments coincide with the US-Saudi Investment Forum...
F4 Uranium Announces TSXV Approval of Debt Settlement
F4 Uranium Announces TSXV Approval of Debt Settlement
Nov 19, 2025
12:46 PM EST, 11/19/2025 (MT Newswires) -- F4 Uranium ( FFUCF ) on Wednesday said it received exchange approvals to settle $332.916 of debt with shares. The company said it will issue 3.03-million shares at a deemed price of $0.11 each to certain insiders and creditors of the company for the amount owing. The company's shares were last seen down...
Viking CEO Credits Strong Bookings To Resilient Customer Base Hungry For Travel
Viking CEO Credits Strong Bookings To Resilient Customer Base Hungry For Travel
Nov 19, 2025
Viking Holdings Ltd. ( VIK ) stock rose after reporting third-quarter 2025 results that topped expectations, delivering adjusted EPS of $1.20 versus the $1.19 estimate and revenue of $1.9996 billion, slightly above the $1.992 billion consensus. Revenue rose 19.1% from a year earlier, supported by an 11% increase in Capacity Passenger Cruise Days (PCDs), 96% occupancy, and higher revenue per...
Oncolytics Biotech Reaches FDA Alignment on Phase 3 Pancreatic Cancer Trial Design
Oncolytics Biotech Reaches FDA Alignment on Phase 3 Pancreatic Cancer Trial Design
Nov 19, 2025
12:45 PM EST, 11/19/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Wednesday it reached alignment with the US Food and Drug Administration on the design of its phase 3 trial testing pelareorep with standard chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma. The alignment was reached during a recent Type C meeting, where Oncolytics and the FDA...
Copyright 2023-2026 - www.financetom.com All Rights Reserved